Characteristics of menopausal hormone therapy use in Russia: results of a large-scale survey of peri- and postmenopausal women

DOI

https://dx.doi.org/10.18565/aig.2025.200

Smetnik A.A., Ivanov I.A., Ermakova E.I., Tabeeva G.I.
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia

Menopause is accompanied by various symptoms that can reduce the quality of life of women and have an impact on society as a whole. The identification of factors that contribute and prevent the use of menopausal hormone therapy (MHT) can provide additional opportunities and perspectives for changing attitudes towards menopause and MHT. The article was prepared by the Russian Society of Gynecological Endocrinology and Menopause (ROSGEM)
Objective: To identify and systematize the causes of the low prevalence of MHT in Russia in terms of patient perception of the problem.
Materials and methods: The study was conducted by Ipsos Comcon through an online survey of 2,536 women aged 45–59 living in Russian cities with populations over 100,000 people. Among them, 1,743 were peri- and postmenopausal women. National representative quotas were established by gender, age, and federal district. All the respondents were divided into three groups: 45–49 years old (n=890), 50–54 years old (n=835) and 55–59 years old (n=811). In addition to the main sample, the survey included 200 women who had some experience in taking MHT over the past 12 months: 100 women took herbal medicines to relieve menopausal symptoms over the past 12 months, and 100 women previously took MHT but stopped using it less than 12 months after starting therapy.
Results: The study revealed that 97.5% of women aged 45–59 years who were in the peri- and post-menopausal stages experienced at least one symptom of menopausal syndrome. The symptoms of menopause were rated as moderate or severe by 74% of patients. The women agree that their quality of life should not deteriorate during menopause (90%1). Endocrinological (55%) and vasomotor (56%) symptoms were often the cause for seeking medical help. Among all the medical professionals, the gynecologist was the primary source of knowledge (93%) about symptoms and therapy. However, gynecologists seldom initiated active discussions about menopause with their patients. Among women who went to the doctor at least once during menopause (n=845/1088), only 20% of women reported that the doctor was the first to initiate a conversation about menopause. Women who were aware of the appropriate treatment method perceived MHT as a therapy that totally relieves peri- and postmenopausal symptoms (49%) compared with non-hormonal therapy (36%) and combined oral contraceptives (23%). Most Russian women (67%) aged 45–59 years who associate health changes with the approach/onset of menopause and do not deny hormone therapy in the future preferred the oral route of MHT administration and only 9% of women chose the transdermal route. The need for information about MHT was reported by about 58% of women. The recommendation to discontinue MHT in 82% of cases (among all doctors) was given by the gynecologist. The lack of a doctor’s administration is also a significant barrier to MHT: the gynecologist did not prescribe MHT to women with severe menopausal symptoms in 21% of cases. Only 10% of women had absolute contraindications to MHT.
Conclusion: The level of MHT use in Russia increased from 1.3% to 6.5% but it remains low compared to developed countries. It is necessary to conduct educational events for gynecologists, other doctors, as well as patients. These events should provide information about menopause, its symptoms, potential long-term health consequences and they should also discuss current ideas about the safety and benefits of MHT.

Authors’ contributions: Smetnik A.A., Ivanov I.A., Ermakova E.I., Tabeeva G.I. – developing the concept of the study, collecting and processing the material, writing the text, editing the article.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was conducted without sponsorship.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Smetnik A.A., Ivanov I.A., Ermakova E.I., Tabeeva G.I.
Characteristics of menopausal hormone therapy use in Russia:
results of a large-scale survey of peri- and postmenopausal women.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (8): 196-208 (in Russian)
https://dx.doi.org/10.18565/aig.2025.200

menopausal hormone therapy

menopause

menopausal syndrome

survey

statistics

prevalence

Full text (in Russian)

Panay N., Ang S.B., Cheshire R., Goldstein S.R., Maki P., Nappi R.E. Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper. Climacteric. 2024; 27(5): 441-57. https://dx.doi.org/10.1080/13697137.2024.2394950
https://www.worldometers.info/demographics/world-demographics/(Accessed 20 Jan 2021).
Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. М.; 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and menopausal symptoms in women. Moscow; 2024 (in Russian)].
Steiner B.M., Berry D.C. The regulation of adipose tissue health by estrogens. Front. Endocrinol. (Lausanne). 2022; 13: 889923. https://dx.doi.org/10.3389/fendo.2022.889923
Li M., Zhu Y., Wei J., Chen L., Chen S., Lai D. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023; 26(2): 95-102. https://dx.doi.org/10.1080/13697137.2022.2153033
Santoro N., Roeca C., Peters B.A., Neal-Perry G. The menopause transition: signs, symptoms, and management options. J. Clin. Endocrinol. Metab. 2021; 106(1): 1-15. https://dx.doi.org/10.1210/clinem/dgaa764
The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://dx.doi.org/10.1097/GME.0000000000002028
Ламбриноудаки И., Армени Э., Гулис Д., Бретц С., Чаусу И., Дурмусоглу Ф., Эрккола Р., Фистонич И., Гамбаччани М., Геукес М., Хамода Х., Хартли К., Хиршберг А.Л., Мечекальски Б., Мендоса Н., Муек А., Сметник А., Штуте П., ван Троценбург М., Рис М. Согласованное заявление Европейского общества по менопаузе и андропаузе: менопауза, благосостояние и здоровье – принципы ведения пациенток. Акушерство и гинекология: новости, мнения, обучение. 2023; 11 Спецвыпуск: 151-68. [Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F., Erkkola R., Fistonic I., Gambacciani M., Geukes M., Hamoda H., Hartley C., Hirschberg A.L., Meczekalski B., Mendoza N., Mueck A., Smetnik A., Stute P., van Trotsenburg M., Rees M. EMAS Consensus Statement Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society. Obstetrics and Gynecology: News, Opinions, Training. 2023; 11 Special Issue: 151-68 (in Russian)].
Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32. [Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I.A. Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Russian Phlebological Association. Obstetrics and Gynecology. 2023; (11): 211-32 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.267
Ашрафян Л.А., Балан В.Е., Баранов И.И., Белая Ж.Е., Бобров С.А., Воронцова А.В., Дубровина С.О., Зазерская И.Е., Иловайская И.А., Карахалис Л.Ю., Лесняк О.М., Мазитова М.И., Подзолкова Н.М., Протасова А.Э., Серов В.Н., Сметник А.А., Сотникова Л.С., Ульрих Е.А., Чернуха Г.Е., Юренева С.В.. Алгоритмы применения менопаузальной гормональной терапии у женщин в период пери- и постменопаузы. Совместная позиция экспертов РОАГ, РАМ, АГЭ, РАОП. Акушерство и гинекология. 2021; 3: 210-21. [Ashrafyan L.A., Balan V.E., Baranov I.I., Belaya Zh.E, Bobrov S.A., Vorontsova A.V., Dubrovina S.O., Zazerskaya I.E., Ilovayskaya I.A., Karakhalis L.Yu., Lesnyak O.M., Mazitova M.I., Podzolkova N.M., Protasova A.E., Serov V.N., Smetnik A.A., Sotnikova L.S., Ulrikh E.A., Chernukha G.E., Yureneva S.V. Algorithms for menopausal hormone therapy during the period of peri- and postmenopause. Joint position statement of RSOG RAM, AGE, RAOP experts. Obstetrics and Gynecology. 2021; (3): 210-21 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.3.210-221
Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ. 2020; 4(6): 23-53. [Ulumbekova G.E., Khudova I.Yu. Demographic, social and economic effects of menopause hormonal therapy. Healthcare Management: news, views, education. Bulletin of VSHOUZ. 2020; 4(6): 23-53 (in Russian)]. https://dx.doi.org/10.24411/2411-8621-2020-14002
ACOG Practice Bulletin No. 141. Obstet. Gynecol. 2014; 123(1): 202-16. https://dx.doi.org/10.1097/01.AOG.0000441353.20693.78
Stuenkel C.A., Davis S.R., Gompel A., Lumsden M.A., Murad M.H., Pinkerton J.V. et al. Treatment of symptoms of the menopause: an endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2015; 100(11): 3975-4011. https://dx.doi.org/10.1210/jc.2015-2236
Cobin R.H., Goodman N.F. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause – 2017 update. Endocr. Pract. 2017; 23(7): 869-80. https://dx.doi.org/10.4158/EP171828.PS
De Melo Pompei L., Machado R.B., Osório Wender M.C., Fernandes C.E., eds. Consenso Brasileiro de Terapêutica Hormonal da Menopausa. São Paulo: Leitura Médica; 2018. Available at: https://www.pfizer.com.br/files/libbs-2018-sobrac-1.pdf
National Institute for Health and Care Excellence. Menopause: diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng23
Meeta M., Digumarti L., Neelam A., Nirmala V., Rashmi S., Sonia M. Clinical practice guidelines on menopause: *an executive summary and recommendations. Journal of Mid-Life Health. 2020; 11(2): 55-95. https://dx.doi.org/10.4103/jmh.JMH_137_20
Hamoda H., Panay N., Pedder H., Arya R., Savvas M. The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod. Health. 2020; 26(4): 181-209. https://dx.doi.org/10.1177/2053369120957514
Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F. et al. Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society. Maturitas. 2022; 163: 1-14. https://dx.doi.org/10.1016/j.maturitas.2022.04.008
Menopause Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. [The 2023 Chinese menopause symptom management and menopausal hormone therapy guidelines]. Zhonghua Fu Chan Ke Za Zhi. 2023; 58(1): 4-21. (in Chinese). https://dx.doi.org/10.3760/cma.j.cn112141-20221118-00706.
Genazzani A.R., Divakar H., Khadilkar S.S., Monteleone P., Evangelisti B., Galal A.F. et al. Counseling in menopausal women: how to address the benefits and risks of menopause hormone therapy. A FIGO position paper. Int. J. Gynaecol. Obstet. 2024; 164(2): 516-30. https://dx.doi.org/10.1002/ijgo.15278
Manson J.E., Aragaki A.K., Rossouw J.E., Anderson G.L., Prentice R.L. , LaCroix A.Z. et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017; 318(10): 927-38. https://dx.doi.org/10.1001/jama.2017.11217
Stevenson J.C., Ren M., Kahler E., Nappi R.E., Tatarchuk T., Simoncini T. et al. Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population. Maturitas. 2024; 190: 108117. https://dx.doi.org/10.1016/j.maturitas.2024.108117
Ren M., Yu Q., Custodio M.G., Simoncini T., Nappi R.E., Tatarchuk T. et al. Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass index. Climacteric. 2025;28(1): 21-7. https://dx.doi.org/10.1080/13697137.2024.2418497
Simoncini T., Ren M., Tatarchuk T., Kahler E., Yu Q., Stevenson J. et al. Impact of low and ultra-low dose estradiol and dydrogesterone on health-related quality of life of postmenopausal women: outcomes from two Phase 3 studies. Gynecological and Reproductive Endocrinology and Metabolism. 2024; 5(2): 74-9. https://dx.doi.org/10.53260/grem.245022
Yu Q., Stevenson J.C., Tatarchuk T., Nappi R.E., Custodio M.G., Kahler E. et al. Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and China. Climacteric. 2024; 27(5):494-500. https://dx.doi.org/10.1080/13697137.2024.2380364
Tatarchuk T., Stevenson J.C., Yu Q., Kahler E., Custodio M.G., Ren M. et al. Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: a pooled safety and tolerability analysis. Gynecol. Endocrinol. 2024; 40(1): 2375577. https://dx.doi.org/10.1080/09513590.2024.2375577

Received 22.07.2025

Accepted 29.08.2025

Аntonina А. Smetnik, PhD, Head of the Department of Gynecological Endocrinology, Associate Professor at the Department of Obstetrics and Gynecology, Institute of Postgraduate Education, V.I. Kulakov National Medical Research Center for Obstetrics and Gynecology, Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4; President of the Russian Society of Specialists in Gynecological Endocrinology and Menopause (ROSGEM), +7(495)531-44-44, a_smetnik@oparina4.ru,
https://orcid.org/0000-0002-0627-3902
Ilya A. Ivanov, PhD, Researcher, Department of Gynecological Endocrinology, V.I. Kulakov National Medical Research Center for Obstetrics and Gynecology,
Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4; Member of the Executive Committee of the Russian Society of Specialists in Gynecological Endocrinology and Menopause, +7(962)980-00-18, doctor.i.ivanov@yandex.ru https://orcid.org/0000-0003-0751-7566
Elena I. Ermakova, PhD, Senior Researcher, Department of Gynecological Endocrinology, V.I. Kulakov National Medical Research Center for Obstetrics and Gynecology, Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4; Vice President of the Russian Society of Specialists in Gynecological Endocrinology and Menopause, +7(916) 848-37-46, e_ermakova@oparina4.ru, https://orcid.org/0000-0002-6629-051X
Gyuzyal I. Tabeeva, PhD, Senior Researcher, Department of Gynecological Endocrinology, V.I. Kulakov National Medical Research Center for Obstetrics and Gynecology, Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4; Scientific Secretary of the Russian Society of Specialists in Gynecological Endocrinology and Menopause, +7(903)199-72-82, doctor.gtab@gmail.com, https://orcid.org/0000-0003-0206-5679

Characteristics of menopausal hormone therapy use in Russia: results of a large-scale survey of peri- and postmenopausal women

Smetnik A.A., Ivanov I.A., Ermakova E.I., Tabeeva G.I.

Keywords

References

About the Authors

Similar Articles